| Primary |
| Psoriasis |
66.7% |
| Product Used For Unknown Indication |
15.4% |
| Dermatitis Atopic |
2.6% |
| Drug Use For Unknown Indication |
2.6% |
| Eczema |
2.6% |
| Foetal Exposure During Pregnancy |
2.6% |
| Guttate Psoriasis |
2.6% |
| Nail Psoriasis |
2.6% |
| Psoriasis Vulgaris |
2.6% |
|
| Rebound Effect |
12.0% |
| Hallucination, Visual |
8.0% |
| Suicidal Ideation |
8.0% |
| Toxic Epidermal Necrolysis |
8.0% |
| Application Site Pruritus |
4.0% |
| Caecitis |
4.0% |
| Circulatory Collapse |
4.0% |
| Drug Exposure During Pregnancy |
4.0% |
| Erythrodermic Psoriasis |
4.0% |
| Folliculitis |
4.0% |
| Incorrect Drug Administration Duration |
4.0% |
| Lip Blister |
4.0% |
| Mycosis Fungoides |
4.0% |
| Osteochondrosis |
4.0% |
| Pharyngeal Oedema |
4.0% |
| Pneumonia |
4.0% |
| Postoperative Wound Infection |
4.0% |
| Pyrexia |
4.0% |
| Rebound Psoriasis |
4.0% |
| Sense Of Oppression |
4.0% |
|
| Secondary |
| Psoriasis |
46.9% |
| Drug Use For Unknown Indication |
7.4% |
| Foetal Exposure During Pregnancy |
7.4% |
| Ankylosing Spondylitis |
4.9% |
| Premedication |
4.9% |
| Prophylaxis Of Neural Tube Defect |
3.7% |
| Vulvovaginal Mycotic Infection |
3.7% |
| Abortion Induced |
2.5% |
| Dermatitis Exfoliative |
2.5% |
| Hepatitis B |
2.5% |
| Polyarthritis |
2.5% |
| Product Used For Unknown Indication |
2.5% |
| Psoriatic Arthropathy |
2.5% |
| Pustular Psoriasis |
2.5% |
| Rheumatoid Arthritis |
2.5% |
| Hepatitis |
1.2% |
|
| Dermatitis Exfoliative |
26.7% |
| Thermal Burn |
20.0% |
| Pustular Psoriasis |
13.3% |
| Ventricular Septal Defect |
13.3% |
| Caecitis |
6.7% |
| Placental Insufficiency |
6.7% |
| Tachycardia |
6.7% |
| Vaginal Haemorrhage |
6.7% |
|
| Concomitant |
| Psoriasis |
40.9% |
| Product Used For Unknown Indication |
19.1% |
| Psoriatic Arthropathy |
10.6% |
| Abortion Induced |
2.7% |
| Drug Use For Unknown Indication |
2.7% |
| Rheumatoid Arthritis |
2.5% |
| Hepatitis C |
2.2% |
| Diabetes Mellitus |
2.0% |
| Supplementation Therapy |
2.0% |
| Hypertension |
1.8% |
| Ankylosing Spondylitis |
1.7% |
| Ill-defined Disorder |
1.5% |
| Prophylaxis Of Neural Tube Defect |
1.5% |
| Vulvovaginal Mycotic Infection |
1.5% |
| Latent Tuberculosis |
1.3% |
| Pain |
1.3% |
| Pustular Psoriasis |
1.3% |
| Erythema |
1.2% |
| Erythema Nodosum |
1.2% |
| Anxiety Disorder |
1.0% |
|
| Psoriasis |
17.3% |
| Pancreatic Carcinoma |
10.7% |
| Ventricular Septal Defect |
8.0% |
| Tuberculosis |
6.7% |
| Placental Insufficiency |
5.3% |
| Renal Neoplasm |
5.3% |
| Emphysema |
4.0% |
| Intervertebral Disc Protrusion |
4.0% |
| Lung Neoplasm Malignant |
4.0% |
| Pneumonia |
4.0% |
| Purpura |
4.0% |
| Thrombocytopenia |
4.0% |
| Vaginal Haemorrhage |
4.0% |
| Chest Pain |
2.7% |
| Colon Cancer |
2.7% |
| Hypotension |
2.7% |
| Hypothyroidism |
2.7% |
| Injection Site Pain |
2.7% |
| Iron Deficiency Anaemia |
2.7% |
| Memory Impairment |
2.7% |
|
